Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene Blue Injection for Prevention of Anastomotic Leakage in Rectal Cancer
NCT07833319Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Nov 2025
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methylene blue in rectal cancer, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Proportion of participants with successful stoma closure at 12 months. Started Nov 2025; status: recruiting.
02
Drugs
methylene blue
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07833319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07833319.